$CHMX
NEXT-ChemX Corporation.

2023 Q3 Form 10-Q Financial Statement

#000149315223029687 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $500.0K
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $403.4K $581.6K $438.3K
YoY Change 4.02% 32.69% -8.01%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $1.330K $1.340K $1.290K
YoY Change -0.75% 3.88% -99.26%
% of Gross Profit
Operating Expenses $403.4K $581.6K $438.3K
YoY Change 4.02% 32.69% 47.08%
Operating Profit -$403.4K -$581.6K -$438.3K
YoY Change 4.02% 32.69% 47.08%
Interest Expense $19.42K $19.20K -$16.22K
YoY Change -242.91% -218.38% 483.45%
% of Operating Profit
Other Income/Expense, Net -$519.4K $183.8K -$16.22K
YoY Change 3721.81% -1233.19% -53.88%
Pretax Income -$922.9K -$397.7K -$454.5K
YoY Change 129.88% -12.5% -5.16%
Income Tax
% Of Pretax Income
Net Earnings -$922.9K -$397.7K -$454.5K
YoY Change 129.88% -12.5% 36.42%
Net Earnings / Revenue -79.54%
Basic Earnings Per Share -$0.03 -$0.01 -$0.02
Diluted Earnings Per Share -$0.03 -$0.01 -$16.28K
COMMON SHARES
Basic Shares Outstanding 28.55M shares 28.45M shares 27.91M shares
Diluted Shares Outstanding 28.50M shares 28.45M shares 27.91M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $162.4K $159.2K $52.55K
YoY Change 180366.67% 202.95% -71.08%
Cash & Equivalents $60.89K $57.68K $52.55K
Short-Term Investments $101.5K $101.5K
Other Short-Term Assets $72.93K $73.25K $1.600K
YoY Change 2414.83% 4478.13% -97.4%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $235.3K $232.5K $54.15K
YoY Change 7760.52% 329.25% -77.74%
LONG-TERM ASSETS
Property, Plant & Equipment $13.96K $15.29K $20.63K
YoY Change -27.66% -25.87% 38.42%
Goodwill
YoY Change
Intangibles $3.150M $3.150M $3.150M
YoY Change 0.0% 0.0%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.164M $3.165M $3.171M
YoY Change -0.17% -0.17% -5.07%
TOTAL ASSETS
Total Short-Term Assets $235.3K $232.5K $54.15K
Total Long-Term Assets $3.164M $3.165M $3.171M
Total Assets $3.399M $3.398M $3.225M
YoY Change 7.16% 5.36% -10.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $573.7K $525.6K $557.0K
YoY Change -8.51% -5.65% 802.82%
Accrued Expenses $1.510M $1.342M $720.6K
YoY Change 73.94% 86.28% 26006.88%
Deferred Revenue
YoY Change
Short-Term Debt $850.1K $641.9K $302.9K
YoY Change 99.56% 111.91% 1919.4%
Long-Term Debt Due $362.5K
YoY Change 1018.83%
Total Short-Term Liabilities $3.446M $3.022M $1.943M
YoY Change 57.8% 55.52% 1636.99%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.446M $3.022M $1.943M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $3.446M $3.022M $1.943M
YoY Change 57.8% 55.52% 1636.99%
SHAREHOLDERS EQUITY
Retained Earnings -$5.471M -$4.548M -$2.791M
YoY Change 71.36% 62.95%
Common Stock $28.55K $28.45K $27.91K
YoY Change 1.74% 1.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$46.69K $376.2K $1.282M
YoY Change
Total Liabilities & Shareholders Equity $3.399M $3.398M $3.225M
YoY Change 7.16% 5.36% -10.0%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$922.9K -$397.7K -$454.5K
YoY Change 129.88% -12.5% 36.42%
Depreciation, Depletion And Amortization $1.330K $1.340K $1.290K
YoY Change -0.75% 3.88% -99.26%
Cash From Operating Activities -$196.8K $140.5K -$202.7K
YoY Change 12.09% -169.32% 26.81%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$1.580K
YoY Change -100.0% -89.57%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 $0.00 -$1.580K
YoY Change -100.0% -89.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 200.0K -225.0K 238.8K
YoY Change 62.47% -194.23% -29.77%
NET CHANGE
Cash From Operating Activities -196.8K 140.5K -202.7K
Cash From Investing Activities 0.000 0.000 -1.580K
Cash From Financing Activities 200.0K -225.0K 238.8K
Net Change In Cash 3.210K -84.52K 34.56K
YoY Change -106.12% -344.56% -79.06%
FREE CASH FLOW
Cash From Operating Activities -$196.8K $140.5K -$202.7K
Capital Expenditures $0.00 $0.00 -$1.580K
Free Cash Flow -$196.8K $140.5K -$201.1K
YoY Change 12.09% -169.87% 38.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001657045
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
usd
CY2022Q4 CHMX Due To Other Related Parties Current
DueToOtherRelatedPartiesCurrent
usd
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
usd
CY2022Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
usd
us-gaap Other Noncash Income
OtherNoncashIncome
usd
CHMX Consultant Commission Paid In Third Party Stock
ConsultantCommissionPaidInThirdPartyStock
usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
CHMX Common Stock Issued On Conversion Of Related Party Notes Payable And Accrued Interest
CommonStockIssuedOnConversionOfRelatedPartyNotesPayableAndAccruedInterest
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-56379
dei Entity Registrant Name
EntityRegistrantName
NEXT-ChemX Corporation
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
32-0446353
dei Entity Address Address Line1
EntityAddressAddressLine1
1980 Festival Plaza Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Summerlin South, 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Las Vegas
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
89135
dei City Area Code
CityAreaCode
(725)
dei Local Phone Number
LocalPhoneNumber
867-0789
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28546834 shares
CY2023Q2 us-gaap Cash
Cash
57679 usd
CY2022Q4 us-gaap Cash
Cash
28355 usd
CY2023Q2 us-gaap Short Term Investments
ShortTermInvestments
101525 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73253 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22169 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
232457 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
50524 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15289 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17957 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3150114 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3150114 usd
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
3165403 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
3168071 usd
CY2023Q2 us-gaap Assets
Assets
3397860 usd
CY2022Q4 us-gaap Assets
Assets
3218595 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1867818 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1548740 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
511980 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
11980 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
625000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
926007 usd
CY2023Q2 CHMX Due To Other Related Parties Current
DueToOtherRelatedPartiesCurrent
16890 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3021688 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2486727 usd
CY2023Q2 us-gaap Liabilities
Liabilities
3021688 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2486727 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28446834 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28446834 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
28346834 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28346834 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
28447 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28347 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4896153 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4396253 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4548428 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-3692732 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
376172 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
731868 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3397860 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3218595 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
581572 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
438301 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1018225 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
812410 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
581572 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
438301 usd
us-gaap Operating Expenses
OperatingExpenses
1018225 usd
us-gaap Operating Expenses
OperatingExpenses
812410 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-581572 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-438301 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-1018225 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-812410 usd
CY2023Q2 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
203050 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
203050 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
19201 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
16224 usd
us-gaap Interest Expense
InterestExpense
40521 usd
us-gaap Interest Expense
InterestExpense
30005 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
183849 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-16224 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
162529 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30005 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-397723 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-454525 usd
us-gaap Net Income Loss
NetIncomeLoss
-855696 usd
us-gaap Net Income Loss
NetIncomeLoss
-842415 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28446834 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28446834 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27914383 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27914383 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28410922 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28410922 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27914383 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27914383 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28446834 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27914383 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28410922 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27914383 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
731868 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-457973 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
773895 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-397723 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
376172 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1712486 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-387890 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1324596 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
1324596 usd
CY2022Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
351361 usd
CY2022Q2 CHMX Stock Issued During Period Value Conversion Of Related Party
StockIssuedDuringPeriodValueConversionOfRelatedParty
60459 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-454525 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-454525 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1281891 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1281891 usd
us-gaap Net Income Loss
NetIncomeLoss
-855696 usd
us-gaap Net Income Loss
NetIncomeLoss
-842415 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2668 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
2492 usd
us-gaap Other Noncash Income
OtherNoncashIncome
203050 usd
CHMX Consultant Commission Paid In Third Party Stock
ConsultantCommissionPaidInThirdPartyStock
101525 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
51084 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
835968 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
526618 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-169669 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-313305 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1577 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1577 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
500000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
60000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
75000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
301007 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
4000 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
376007 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
198993 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
357007 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29324 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
42125 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
28355 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10429 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
57679 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52554 usd
CHMX Common Stock Issued On Conversion Of Related Party Notes Payable And Accrued Interest
CommonStockIssuedOnConversionOfRelatedPartyNotesPayableAndAccruedInterest
60459 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4548428 usd
CY2023Q2 us-gaap Revenues
Revenues
500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-855696 usd
us-gaap Net Income Loss
NetIncomeLoss
-842415 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-169669 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-313305 usd
CY2023Q1 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
500000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
308161 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
297000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
776638 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_841_eus-gaap--UseOfEstimates_z9wGbPGpNMdl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_864_zG7lsPzX9bXl">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Adjustment For Amortization
AdjustmentForAmortization
3150114 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
25981 usd
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1867818 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1548740 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73253 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22169 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
51084 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
3150114 usd
CY2023Q2 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
525568 usd
CY2022Q4 us-gaap Accounts Payable Current And Noncurrent
AccountsPayableCurrentAndNoncurrent
471567 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1305828 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1051192 usd
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
36422 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
426006.86 usd
CY2022 us-gaap Debt Instrument Redemption Price Percentage
DebtInstrumentRedemptionPricePercentage
0.08 pure
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
376007 usd
CY2023Q2 us-gaap Notes And Loans Payable Current
NotesAndLoansPayableCurrent
50000 usd
CY2022Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
500000 usd
CY2022Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
CY2023Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
75000 usd
CY2023Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10 pure
us-gaap Interest Expense
InterestExpense
40521 usd
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
28446834 shares
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
100000 shares

Files In Submission

Name View Source Status
0001493152-23-029687-index-headers.html Edgar Link pending
0001493152-23-029687-index.html Edgar Link pending
0001493152-23-029687.txt Edgar Link pending
0001493152-23-029687-xbrl.zip Edgar Link pending
chmx-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
form10-q_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
chmx-20230630_cal.xml Edgar Link unprocessable
chmx-20230630_pre.xml Edgar Link unprocessable
chmx-20230630_def.xml Edgar Link unprocessable
chmx-20230630_lab.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending